Overview

SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)

Status:
Recruiting

Trial end date:
2022-10-21

Target enrollment:

Participant gender:

Summary

Primary Objectives: o Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. o Part 2: To assess the antitumor activity of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Secondary Objectives: - To assess the safety and tolerability of SAR408701 in combination with ramucirumab - To assess the durability of the response to treatment with SAR408701 in combination with ramucirumab - To assess efficacy of SAR408701 in combination with ramucirumab on progression free survival - To assess the pharmacokinetic (PK) profile of SAR408701 and ramucirumab when given in combination - To assess the immunogenicity of SAR408701 when given in combination with ramucirumab

Phase:

Phase 2

Details

Lead Sponsor:

Sanofi

Treatments:

Ramucirumab